Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28767601 | 0.90 | ACHE (0.39) | ACHEEZH2MAOAEZH1KDM1A | |
| SCHEMBL21114613 | 0.85 | GPR119 (0.40) | ACHEEZH2ALDH1A1CYP2C9ALOX15 | |
| SCHEMBL21155772 | 0.85 | GPR119 (0.40) | ACHEEZH2ALDH1A1CYP2C9ALOX15 | |
| SCHEMBL19725554 | 0.85 | GPR119 (0.40) | ACHEEZH2ALDH1A1CYP2C9ALOX15 | |
| SCHEMBL19725556 | 0.83 | KDM1A (0.39) | ACHEEZH2MAOAEZH1KDM1A | |
| SCHEMBL28700718 | 0.71 | GPR119 (0.43) | EZH2MAOAEZH1KDM1AHDAC8 | |
| SCHEMBL28767609 | 0.70 | KDM1A (0.48) | MAOAKDM1A | |
| SCHEMBL18845512 | 0.70 | KDM1A (0.43) | EZH2MAOAKDM1AHDAC8HDAC6 | |
| SCHEMBL12832563 | 0.70 | KDM1A (0.39) | MAOAKDM1A | |
| SCHEMBL19725466 | 0.69 | KDM1A (0.43) | EZH2MAOAEZH1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873292-B2 | Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20190210998-A1 | TRANS-INDOLINE CYCLOPROPYLAMINE CHEMICAL COMPOUND, AND METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210998-A1 | TRANS-INDOLINE CYCLOPROPYLAMINE CHEMICAL COMPOUND, AND METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | INMT, IDO1, TPH1 | ACHE 794/4885EZH2 124/4885MAOA 197/4885 |
| US-11873292-B2 | Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof | INMT, IDO1, TPH1 | ACHE 794/4885EZH2 124/4885MAOA 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.